Evidence map›Paper›PMID 29762666›Full record

ArticleInflammatory bowel diseases2018

Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia.

Andrew D Beggs, Jonathan James, Germaine Caldwell, Toby Prout, Mark P Dilworth, Phillipe Taniere, Tariq Iqbal, Dion G Morton, Glenn Matthews

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Inflammatory bowel diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrew D BeggsInstitute of Cancer and Genomic Science, University of Birmingham.
Jonathan JamesInstitute of Cancer and Genomic Science, University of Birmingham.
Germaine CaldwellInstitute of Cancer and Genomic Science, University of Birmingham.
Toby ProutInstitute of Cancer and Genomic Science, University of Birmingham.
Mark P DilworthInstitute of Cancer and Genomic Science, University of Birmingham.
Phillipe TaniereInstitute of Cancer and Genomic Science, University of Birmingham.
Tariq IqbalInstitute of Cancer and Genomic Science, University of Birmingham.
Dion G MortonInstitute of Cancer and Genomic Science, University of Birmingham.
Glenn MatthewsInstitute of Cancer and Genomic Science, University of Birmingham.
University of Birmingham · GB

Funding

Cancer Research UK 24430Cancer Research UK C31641/A23923Department of Health 11/100/29Medical Research Council MR/M009157/1Wellcome TrustWellcome Trust 102732/Z/13/Z
6 · The paper itself

Abstract

Background and aims: Ulcerative colitis (UC) is associated with a higher background risk of dysplasia and/or neoplasia due to chronic inflammation. There exist few biomarkers for identification of patients with dysplasia, and targeted biopsies in this group of patients are inaccurate in reliably identifying dysplasia. We aimed to examine the epigenome of UC dysplasia and to identify and validate potential biomarkers. Methods: Colonic samples from patients with UC-associated dysplasia or neoplasia underwent epigenome-wide analysis on the Illumina 450K methylation array. Markers were validated by bisulphite pyrosequencing on a secondary validation cohort and accuracy calculated using logistic regression and receiver-operator curves. Results: Twelve samples from 4 patients underwent methylation array analysis and 6 markers (GNG7, VAV3, KIF5C, PIK3R5, TUBB6, and ZNF583) were taken forward for secondary validation on a cohort of 71 colonic biopsy samples consisting of normal uninflamed mucosa from control patients, acute and chronic colitis, "field" mucosa in patients with dysplasia/neoplasia, dysplasia, and neoplasia. Methylation in the beta-tubulin TUBB6 correlated with the presence of dysplasia (P < 0.0001) and accurately discriminated between dysplasia and nondysplastic tissue, even in the apparently normal field mucosa downstream from dysplastic lesions (AUC 0.84, 95% CI 0.81-0.87). Conclusions: Methylation in TUBB6 is a potential biomarker for UC- associated dysplasia. Further validation is needed and is ongoing as part of the ENDCAP-C study.

Indexed as

DNA MethylationAdultBiomarkers, TumorCase-Control StudiesColitis, UlcerativeColonic NeoplasmsColonoscopyFemaleHumansIntestinal MucosaLogistic ModelsMaleMiddle AgedPrecancerous ConditionsROC CurveTubulinBiomarkers, TumorTUBB6 protein, humanTubulin

Identifiers

PMID29762666
PMCPMC6176894
OpenAlexW2803934566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.